G. Hampton

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Garret M Hampton, G. Hampton, Garrett M. Hampton, Garret M. Hampton, G.m. Hampton, Garrett Hampton, Garret Hampton, G. M. Hampton, G M Hampton, G Hampton
Publication record
137 papers · 13,021 citations · H-index 52

PAPERS

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
2018208 citationsauthor #25
Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology
201846 citationsauthor #13
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types
2018144 citationsauthor #19
Abstract 1750: Analysis of non-metastatic HCC patient tumors revealed the significance of cell cycle regulation and tumor immunity in association with overall survival and identified clinically relevant druggable targets
20171 citationsauthor #12
OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
201792 citationsauthor #17
Abstract 2708: A custom gene expression panel for consensus molecular subtype classification of archival primary and metastatic colorectal cancers
20170 citationsauthor #8
Abstract 3631: Whole transcriptome and exome targeted RNA sequencing for FFPE tumor samples from clinical trials
20160 citationsauthor #8
Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
201649 citationsauthor #16
Abstract 4257: Gene expression and genomic drift comparative analysis between patient-derived conditionally reprogrammed cells and original tumors
20160 citationsauthor #8
Abstract 417: A novel predictive biomarker model for MEK sensitivity
20160 citationsauthor #9
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
2016281 citationsauthor #12
Abstract B28: Activating mutations in PIK3CB confer resistance to PI3K inhibition in PTEN-deficient breast cancer and define a novel oncogenic role for p110β
20160 citationsauthor #6
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
201626 citationsauthor #18
Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.
201665 citationsauthor #6
A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
201664 citationsauthor #9
Abstract 1837: Comprehensive RNA-seq transcriptome interrogation of paired hepatocellular carcinoma and cirrhosis tissues revealed significant molecular features of disease evolution and modulation of tumor immunity
20160 citationsauthor #12
Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers
20161 citationsauthor #15
Abstract 5155: Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter
20160 citationsauthor #18
Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter
201674 citationsauthor #18
Abstract B03: Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
20150 citationsauthor #8
Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer
20152 citationsauthor #16
Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers
201435 citationsauthor #15
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.
201449 citationsauthor #16
Discovery and development of DNA methylation-based biomarkers for lung cancer.
201426 citationsauthor #9
High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing
201463 citationsauthor #12
Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
201431 citationsauthor #15
Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary
20136 citationsauthor #10
Abstract 3462: High-throughput qRT-PCR expression profiling of estrogen receptor positive breast tumors.
20130 citationsauthor #7
Abstract 3479: Sensitivity of endometrial cancer cells to inhibitors targeting different nodes of the PI3K pathway and their combination with a MEK inhibitor.
20130 citationsauthor #7
Abstract 3505: Development of robust copy number assays for tumor FFPE tissues.
20130 citationsauthor #7
Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
201373 citationsauthor #14
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma
20138 citationsauthor #17
Companion Diagnostics & Cancer Biomarkers HGFasaCirculatingBiomarker ofOnartuzumabTreatment in Patients with Advanced Solid Tumors
20130 citationsauthor #10
Abstract B024: Comprehensive biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers
20130 citationsauthor #15
High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck
201369 citationsauthor #16
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
201376 citationsauthor #8
HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
201328 citationsauthor #10
Abstract 1203: Molecular stratification of bladder cancer reveals distinct subtypes associated with unique clinical behaviors.
20130 citationsauthor #13
Abstract 4567: Biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors.
20130 citationsauthor #12
HGFasaCirculatingBiomarkerofOnartuzumabTreatmentin Patients with Advanced Solid Tumors
20130 citationsauthor #10
Abstract 3395: BCR-Abl independent, Abl-TKI-therapy-resistant CML cells show enhanced sensitivity to GDC0941.
20130 citationsauthor #7
HGFasaCirculatingBiomarker ofOnartuzumabTreatment in Patients with Advanced Solid Tumors
20130 citationsauthor #10
Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck
20132 citationsauthor #16
Abstract 5609: Mechanisms of acquired resistance to selective PI3K inhibitors in breast cancer cell lines
20120 citationsauthor #6
Biological Subsets of Non – Small Cell Lung Cancer
20121 citationsauthor #13
Abstract A29: Different PIK3CA activation mutations can lead to distinct signaling mechanisms and EGFR inhibitor sensitivities in colorectal cancer cells
20120 citationsauthor #3
HER2 as a Therapeutic Target in Ovarian Cancer
20129 citationsauthor #3
Abstract B62: Multiple genomic aberrations in BCR-ABL inhibitor-resistant cells lead to sensitivity towards MEK inhibition
20120 citationsauthor #4
Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
2012186 citationsauthor #13
Abstract 4821: Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
20120 citationsauthor #9
Abstract 1732: DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer
20120 citationsauthor #5
Abstract 1147: Molecular characterization of PI3K pathway alterations in non-small cell lung carcinoma
20120 citationsauthor #7
495 The PI3K/mTOR Inhibitor GDC-0980 Demonstrates Target Engagement and Pathway Modulation in Tumor Tissue at Tolerated Doses
20121 citationsauthor #6
DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
201282 citationsauthor #13
Predictive Biomarkers and Personalized Medicine Evaluation of Circulating Tumor Cells and Circulating Tumor DNA inNon – SmallCell LungCancer : AssociationwithClinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
20120 citationsauthor #8
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
2012209 citationsauthor #17
Prostate cancer – a biomarker perspective
201231 citationsauthor #4
Abstract 3153: Detecting PTEN deletions in prostate cancer using circulating tumor cells
20110 citationsauthor #5
Abstract 3180: Mutation detection in circulating free DNA using mutant-enriched PCR and digital PCR
20110 citationsauthor #7
Abstract 4116: Predictive biomarkers for the PI3 kinase inhibitor GDC-0941 in NSCLC
20110 citationsauthor #9
Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
2011411 citationsauthor #8
Abstract 3140: Analysis of candidate phosphatidylinositol 3’ kinase inhibitor biomarkers in matched synchronous primary and metastatic breast cancer tumors
20110 citationsauthor #11
595 Preclinical activity and the role of biomarkers of sensitivity to the selective phosphatidylinositol 3'kinase inhibitor GDC-0941 in breast cancer
20100 citationsauthor #10
Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
201091 citationsauthor #13
Abstract LB-221: Differential aberrant DNA methylation predicts for Tarceva response in NSCLC
20100 citationsauthor #9
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
2010103 citationsauthor #13
Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination.
200945 citationsauthor #6
Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis.
200953 citationsauthor #3
Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration
2008166 citationsauthor #4
Prediction of drug combination chemosensitivity in human bladder cancer
200752 citationsauthor #5
Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector
200725 citationsauthor #3
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole
2007105 citationsauthor #8
Aromatase inhibitors--gene discovery.
200723 citationsauthor #6
Genomics in cancer drug discovery and development
20070 citationsauthor #1
An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma
200730 citationsauthor #17
Overexpression of CEBPβ correlates with decreased TFF1 in gastric cancer
200629 citationsauthor #3
635: CD24 is a Biomarker and Mediator For Urologic Neoplasia
20060 citationsauthor #3
Region at 11 q 23 . 3 of Heterozygosity in Breast Cancer : Identification of a New Definition and Refinement of Chromosome 11 Regions of Loss Updated
20060 citationsauthor #3
Loss of Heterozygosity for Chromosome 11 in Primary Human Breast Tumors Is Associated with Poor Survival after Metastasis 1
20060 citationsauthor #2
Using changes in gene expression as assessed by microarray analysis of sequential tumour biopsies to predict response to neoadjuvant therapy with letrozole
20061 citationsauthor #6
Comprehensive analysis of HE4 expression in normal and malignant human tissues
2006447 citationsauthor #2
Transcriptional regulation in human bladder cancer cells by RalA and RalB via both independent and overlapping pathways
20060 citationsauthor #5
Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis
2006111 citationsauthor #10
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
200634 citationsauthor #17
A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase.
2006198 citationsauthor #8
A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways.
200650 citationsauthor #4
The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer.
2006155 citationsauthor #7
Loss of Heterozygosity for Chromosome 11 in Primary Human Breast Tumors Is Associated with Poor Survival after Metastasis1
20060 citationsauthor #2
Cancer chemosensitivity prediction of drug combinations using single drug responses and microarray profiling data
20060 citationsauthor #4
Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole
200510 citationsauthor #6
Mapping of candidate tumor suppressor genes on chromosome 12 in adenoid cystic carcinoma
200537 citationsauthor #2
Analysis and validation of differential gene expression in serous ovarian tumors of varying grade and malignant potential
20050 citationsauthor #10
595: The Metastasis Suppressor Gene RhoGDI2 Reduceslung Metastasis in Human Bladder Cancer Via Downregulation of Endothelin 1
20050 citationsauthor #4
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential
2005211 citationsauthor #17
Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2.
2005110 citationsauthor #7
Altered expression of TFF-1 and CES-2 in Barrett's Esophagus and associated adenocarcinomas.
200526 citationsauthor #10
Erratum: Loss of heterozygosity in sporadic human breast carcinoma: A common region between 11q22 and 11q23.3 (Cancer Research (September 1994) 54 (4586-4589)
200418 citationsauthor #1
Profiling the Evolution of Human Metastatic Bladder Cancer
200493 citationsauthor #6
Reduced Expression of Metastasis Suppressor RhoGDI2 Is Associated with Decreased Survival for Patients with Bladder Cancer
2004167 citationsauthor #5
Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin
2004133 citationsauthor #9

TIMELINE

1994 306 citations

1995 215 citations

1996 113 citations

1997 139 citations

1999 52 citations

2000 24 citations

2001 2,935 citations

2002 3,005 citations

2003 1,202 citations

2004 476 citations

2005 394 citations

2006 1,025 citations

2007 235 citations

2008 166 citations

2009 98 citations

2010 194 citations

2011 411 citations

2012 519 citations

2013 262 citations

2014 204 citations

2015 2 citations

2016 560 citations

2017 93 citations

2018 398 citations

G. Hampton

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT